Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. - Wikidata - wikimedia - TriplyDB

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

http://www.wikidata.org/entity/Q37207049

about

Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals Small-molecule inhibitors of the Myc oncoprotein A causal relation between bioluminescence and oxygen to quantify the cell niche The tumor microenvironment shapes hallmarks of mature B-cell malignancies.BET bromodomain inhibition as a therapeutic strategy to target c-Myc Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Niche-based screening identifies small-molecule inhibitors of leukemia stem cells CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells.Microenvironmental regulation of therapeutic response in cancer Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment.Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics Directed molecular evolution reveals Gaussia luciferase variants with enhanced light output stability.Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support.A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay.Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.Ectoenzyme switches the surface of magnetic nanoparticles for selective binding of cancer cells.Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.

P2860

Q26801410-15B100BC-5B42-443A-9EFF-276B387E5AC5 Q26822700-A1647468-C416-4ADA-81A0-E2C64B3D37F8 Q26826863-74AD78DB-A7B6-4C9B-BB15-FC61BAAE7754 Q27006069-033C6BD9-A5D1-4893-A50B-979EA5ABA3F9 Q27025648-7E73A6DD-1BE0-4A22-9827-3C4930B6206A Q27332197-D7C9A60E-B6A2-40F9-B3B3-50208FC4FA60 Q27687567-38FEB038-28E9-4512-AAAE-489FA2C77070 Q28247024-14CD1445-390C-4A3A-9931-376394C65C20 Q28383385-E258F520-88C1-4A17-9227-DC6AF02C9B56 Q28384647-50445316-CED1-45BA-B3C5-13061A4DF704 Q28478937-C281C20C-FFFA-40C3-89C1-BEDD9DEC4ECF Q28540339-3D629FB0-9DB3-4F36-9D89-A09EE6B50DE2 Q28583196-F23BDAD0-2A22-4184-9DC7-A1F35143CF60 Q29614274-4BE04544-DF86-4489-8B76-41B01FCEA136 Q29617359-A3D802E3-EA64-4958-A25B-2D8EC3971644 Q33563509-7C05FA0C-E2B5-446E-A33B-108A7DE66642 Q33587369-784FC938-96CA-4386-BF23-53EABEBBF3B4 Q33641541-5B18F1FB-F733-48C6-86A2-118C12CDC80B Q33654609-35CE5F0A-E982-4D9E-8E07-5F14CE32A507 Q33702365-64C890DB-E63E-4B78-8E02-A9F92EFF5B7A Q33745075-58D7CCA7-7C58-449B-A7C1-F1E5554839F8 Q33808741-0A68DD8F-1B3D-404D-9991-033146FFEF66 Q33852603-31EB7A17-ADB8-4FB9-906D-23BFCE5B68D7 Q33916413-3118E63F-6FE7-4A80-85C8-4DB896C0C02B Q34346483-66A1BCAB-6453-483C-829A-FF11956C9816 Q34458274-6C20F0AE-3627-4B9C-A33D-F680D253D765 Q34593139-03F2300C-22BE-48A9-B5F4-E506108F6CEF Q34608271-E44EF59A-4DE8-4475-B7F5-E0187B24807E Q34669402-88EDC9A4-1DE3-4D04-9782-A93E19C2A018 Q34773850-29C84DAE-AECC-4124-B9AD-ABC002B5C5DF Q34957024-75C01801-6630-4DB8-8730-2D77F1D00982 Q34976801-76CE4B44-BB85-4592-B2B4-38EFDBC1F2D1 Q35107127-80BA6EAC-1F80-4DB3-817F-F77578C23485 Q35153559-D6FA5D9C-D2BB-42FC-BEBD-449D85D31783 Q35190691-16B9427D-67B7-4AE6-99ED-F1F7A8A82567 Q35205375-CE6FD63F-188A-4165-B6EC-9C9C4AE17671 Q35219539-74D2738D-9B9D-4162-A27B-48CD65AB941D Q35409569-97804DC6-6E2C-4FFE-9621-093128CE769B Q35552693-06019510-0466-4A89-94DD-C15C07398CD8 Q35552719-DF3FA150-9876-4467-A09F-F97AA92E8C89

P2860

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

http://www.wikidata.org/entity/Q37207049

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tumor cell-specific biolumines ...... s to anticancer drug activity.

@en

Tumor cell-specific biolumines ...... s to anticancer drug activity.

@nl

type

label

Tumor cell-specific biolumines ...... s to anticancer drug activity.

@en

Tumor cell-specific biolumines ...... s to anticancer drug activity.

@nl

prefLabel

Tumor cell-specific biolumines ...... s to anticancer drug activity.

@en

Tumor cell-specific biolumines ...... s to anticancer drug activity.

@nl

P1433

Q37207049-24A1488E-737A-4DDD-BC2E-EC63900D946F

P1476

Q37207049-AA1296B9-7EFC-4263-BA7D-FCCA422D354C

P2093

Q37207049-0EBC2212-7685-4DEF-9264-D5A26B47AE8E

Q37207049-0EFE2466-6875-403A-9E51-535B5BB95042

Q37207049-6C689769-00C0-4172-A0B3-3C043C88371E

Q37207049-7CD9E830-799F-4CD4-A8ED-44585C51F19A

Q37207049-A99356BB-08DA-4AB8-A7A7-0E228CE7B2CC

Q37207049-ABD63DF1-55A0-44A2-B54B-33D58ACCCF32

Q37207049-ADACE14A-879A-4C92-8CC0-770E582EC886

Q37207049-ADC3D9F2-FDC0-4CBD-8A0C-E2FB56CF8A1E

Q37207049-D2646D6C-EAB6-454F-938C-A7A0DA9B9408

Q37207049-E9C402DF-0FC0-4D7E-BC39-442029D0D6D9

P2860

Q37207049-022B322D-67C4-40D9-B272-320B92743283

Q37207049-0C7AFE50-6896-4B85-96D7-BC1F3A774A01

Q37207049-11400278-8490-40B7-89C8-22A73EB054C6

Q37207049-14367589-455D-42EB-AD1D-9939FC27CE87

Q37207049-34D47D14-9EB8-4386-87A3-76F3E74645F9

Q37207049-4B5BE8C2-E057-478B-8366-A1D2B2F7262A

Q37207049-4C99CC3D-5E35-4C08-81F1-729F9573DC58

Q37207049-4F4F8F7C-213C-4199-8459-0194B542A4A0

Q37207049-506296D8-5014-49D0-B5BC-71B8DEE6C6CA

Q37207049-54ECC6CD-907B-490B-8729-137A13356279

P2888

Q37207049-AD965E10-DCF3-4604-919A-66DF255E6EC8

P304

Q37207049-BB192579-C519-4779-9E66-5A22C3C01823

P31

Q37207049-A0709D57-FC11-4650-9915-5BE14DA09657

P356

Q37207049-2BBE8AFC-AC97-489A-9CDE-2B216EBE2723

P407

Q37207049-C2DC94E1-E07D-4378-85E7-E2DB21C81537

P433

Q37207049-867F2661-8836-4380-B176-1B3874E434A2

P478

Q37207049-D67302BD-5684-4F5B-A0A0-E3149809FF3D

P50

Q37207049-0B9247E6-9C76-4F4F-8313-A498DDCCAB72

Q37207049-65E78A8C-B48A-49DD-BDFC-DE004668499D

Q37207049-67ED41E3-A3FD-48FC-AF72-56E2D04F087B

P577

Q37207049-63556BD6-383F-446E-9EEA-5F3D7208FCF0

P5875

Q37207049-02836FE6-EC53-4701-97C6-27DA166B1E94

P698

Q37207049-397273C2-DCCE-4583-A90C-DF2791FFB163

P921

Q37207049-E36EEEF7-585D-4D2B-A759-3B90A7C61BB0

P932

Q37207049-5A650995-E3B1-471D-9822-BC4B2ACC18E0

P356

P1433

Nature Medicine

P1476

Tumor cell-specific biolumines ...... es to anticancer drug activity

@en

P2093

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

D Corey Geer

http://www.w3.org/2001/XMLSchema#string

Douglas W McMillin

http://www.w3.org/2001/XMLSchema#string

Ellen Weisberg

http://www.w3.org/2001/XMLSchema#string

Jake Delmore

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

Joseph M Negri

http://www.w3.org/2001/XMLSchema#string

Nicholas Mitsiades

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Robert L Schlossman

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene

An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation

XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

Friends or foes - bipolar effects of the tumour stroma in cancer

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

P2888

P304

483-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2112

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2010-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41944335

http://www.w3.org/2001/XMLSchema#string

P698

20228816

http://www.w3.org/2001/XMLSchema#string

P921

bioluminescence

P932

3786785

http://www.w3.org/2001/XMLSchema#string